Comparative Values of Tumour Markers in Breast Cancer
Author Information
Author(s): J.L. Cazin, P. Gosselin, B. Boniface, M.C. Demaille, M. Boniface, A. Demaille
Primary Institution: Laboratoire de Radiopharmacie et Pharmacie Clinique, Centre Oscar Lambret, Lille, France
Hypothesis
The study aims to compare the clinical values of CEA and CA 15.3 in women with breast cancer.
Conclusion
CA 15.3 is a more effective marker than CEA for evaluating breast cancer.
Supporting Evidence
- CA 15.3 showed better sensitivity and similar specificity compared to CEA.
- The area under the ROC curve for CA 15.3 was significantly higher than for CEA.
- ROC curve analysis allows for a more objective comparison of diagnostic tests.
Takeaway
This study looked at two blood tests for breast cancer and found that one test is better at finding cancer than the other.
Methodology
Blood samples were taken from 30 healthy women and 60 women with confirmed breast cancer, and the levels of CEA and CA 15.3 were measured and compared using ROC curve analysis.
Limitations
Accurate comparisons were difficult due to lack of information about tumour staging and variability in CEA assays.
Participant Demographics
30 healthy control women and 60 women with histologically confirmed breast carcinoma.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website